Evidence map›Paper›PMID 34773667›Full record

ReviewAdvanced materials (Deerfield Beach, Fla.)2022

Bioinks and Bioprinting Strategies for Skeletal Muscle Tissue Engineering.

Mohamadmahdi Samandari, Jacob Quint, Alejandra Rodríguez-delaRosa, Indranil Sinha, Olivier Pourquié, Ali Tamayol

Abstract readReview
In one paragraph

Review in Advanced materials (Deerfield Beach, Fla.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Multifunctional scaffold based on TiMaterials today. Bio · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohamadmahdi SamandariDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, CT, 06030, USA.
Jacob QuintDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, CT, 06030, USA.
Alejandra Rodríguez-delaRosaDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Indranil SinhaDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02139, USA.
Olivier PourquiéDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Ali TamayolDepartment of Biomedical Engineering, University of Connecticut Health Center, Farmington, CT, 06030, USA.ORCID https://orcid.org/0000-0003-1801-2889

Funding

Suturable bioprinted vascularized muscle constructs for treatment of skeletal muscle lossR01AR077132 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SHIN, SU RYON, TAMAYOL, ALI · 2021 to 2025
$2.6M
Microengineered scaffolds carrying patient-specific cells and growth factors for treatment of volumetric muscle lossR01AR073822 · NIAMS · UNIVERSITY OF NEBRASKA LINCOLN · PI TAMAYOL, ALI · 2018 to 2022
$1.8M
Regenerative Engineering of Musculoskeletal Tissues- a Convergence Doctoral Training ProgramT32AR079114 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI LAURENCIN, CATO T. · 2021 to 2025
$1.1M
NIAMS NIH HHS R01 AR073822NIAMS NIH HHS R01 AR077132NIAMS NIH HHS T32 AR079114NIH HHS R01-AR073822NIH HHS R01-AR077132-01A1
6 · The paper itself

Abstract

Skeletal muscles play important roles in critical body functions and their injury or disease can lead to limitation of mobility and loss of independence. Current treatments result in variable functional recovery, while reconstructive surgery, as the gold-standard approach, is limited due to donor shortage, donor-site morbidity, and limited functional recovery. Skeletal muscle tissue engineering (SMTE) has generated enthusiasm as an alternative solution for treatment of injured tissue and serves as a functional disease model. Recently, bioprinting has emerged as a promising tool for recapitulating the complex and highly organized architecture of skeletal muscles at clinically relevant sizes. Here, skeletal muscle physiology, muscle regeneration following injury, and current treatments following muscle loss are discussed, and then bioprinting strategies implemented for SMTE are critically reviewed. Subsequently, recent advancements that have led to improvement of bioprinting strategies to construct large muscle structures, boost myogenesis in vitro and in vivo, and enhance tissue integration are discussed. Bioinks for muscle bioprinting, as an essential part of any bioprinting strategy, are discussed, and their benefits, limitations, and areas to be improved are highlighted. Finally, the directions the field should expand to make bioprinting strategies more translational and overcome the clinical unmet needs are discussed.

Indexed as

BioprintingMuscle, SkeletalPrinting, Three-DimensionalTissue EngineeringTissue Scaffoldsbioinksbioprintingmuscle injuryskeletal musclestissue engineering

Identifiers

PMID34773667
PMCPMC8957559

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.